Abu-Sbeih H, et al. - Given that immune-mediated diarrhea and colitis (IMDC) often leads to suspension of immune checkpoint inhibitor (ICI) therapy, researchers performed this retrospective multicenter study to determine the rate of and risk factors for IMDC recurrence following ICI resumption. Of overall 167 patients who resumed ICI therapy post-improvement of IMDC, recurrent IMDC was reported by one third. Post-resumption of anti–programmed cell death 1 or ligand 1 (PD-1/L1), less frequent recurrence was noted, as compared to that noted after anti–cytotoxic T-cell lymphocyte-4 resumption. A higher risk of IMDC recurrence was observed in patients who were treated with anti–PD-1/L1 therapy at initial IMDC, as revealed on multivariable logistic regression. A higher risk of IMDC recurrence was present in patients who needed immunosuppression for initial IMDC or had a longer duration of IMDC symptoms in the initial episode.